![BS-181 14361 [Epub ahead of print] PubMed](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M11153_1621563078.gif?v=1621563080)
Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
[Epub ahead of print] PubMed PMID: 29233021
InChiKey: MXOOUCRHWJYCAL-UHFFFAOYSA-N
Pemetrexed Disodium Hydrate stimulates autophagy and apoptosis
InChi: InChI=1S/C21H22ClN3O/c22-18-10-14(12-23)7-8-20(18)26-21-17-6-2-1-4-15(17)11-19(21)25-9-3-5-16(24)13-25/h1-2
PubMed Central PMCID: PMC6711145
BS-181 14361 [Epub ahead of print] PubMedNormal progression through the cell cycle requires the sequential action of cyclin dependent kinases (CDK1, CDK2, CDK4 and CDK6). Deregulation of CDK activity is a feature of almost all cancers and has led to the development of CDK inhibitors as anticancer agents. As such, CDK7 is an target for the anticancer drug development. Computer modeling of CDK7 was used to design potential potent CDK7 inhibitor, which is BS 181. Product information CAS Number:
US$ 290.00
US$ 487.50
US$ 487.50
US$ 123.50
US$ 425.00
US$ 410.00
US$ 250.00
US$ 177.97
US$ 322.48
US$ 180.00
US$ 487.50